Resources from the same session
848MO - Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)
Presenter: Wan Qin Chong
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
850MO - Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163)
Presenter: Nabil Saba
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
867MO - Epigenetic therapy modulates the tumor microenvironment to sensitize anti-PD-1 refractory head and neck cancers to immunotherapy
Presenter: Austin Mattox
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 848MO, 850MO and 867MO
Presenter: Paolo Bossi
Session: Mini oral session: Head and neck cancer
Resources:
Slides
Webcast
851MO - Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)
Presenter: Makoto Tahara
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
LBA37 - Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN)
Presenter: M. Kuruvilla
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Webcast
852MO - REWRITE–GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
Presenter: Joël Castelli
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant 851MO, LBA37 and 852MO
Presenter: Ester Orlandi
Session: Mini oral session: Head and neck cancer
Resources:
Webcast
853MO - Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
Presenter: Jérome Fayette
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Webcast
854MO - Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial
Presenter: Yungan Tao
Session: Mini oral session: Head and neck cancer
Resources:
Abstract
Slides
Webcast